The impact of clinical genome sequencing in a global population with suspected rare genetic disease

Erin Thorpe Venti will present findings from an observational, retrospective analysis of 1,004 underserved individuals from 8 countries with suspected rare genetic disease who received clinical genome sequencing (cGS) through the iHope program, a philanthropic testing access program. 

Overview of Presentation

• The diagnostic yield of cGS was 41.4% across the cohort. Individuals from sites in low- and middle-income countries (LMIC) had a higher diagnostic yield compared to those from sites in high-income countries (HIC).
• cGS impacted the clinician’s diagnostic evaluation (DE) for 76.9% of individuals, with a higher rate in LMIC sites (87.4%) compared to HIC sites (70.1%). Positive test results led to a substantial increase in DE (64.2 times more likely), showing the impact of accurate diagnoses on clinical practices.
• cGS resulted in a change of management (COM) for 41.1% of individuals, including new specialty referrals, imaging, therapeutic interventions, and palliative care. The COM increased to 69.2% when genetic counseling and avoidance of additional testing we also considered.
• Individuals from LMIC sites were as likely as their HIC counterparts to experience a change in diagnostic evaluation and change of management, suggesting that increased access to genomic testing may support diagnostic equity and the reduction of global health care disparities.

Missed the webinar? Here's a highlight:

ASHG Members get access to our recorded webinars for free! Log in to watch the rest of the webinar.